Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vigonvita Life Sciences Co's ROE % for the quarter that ended in Dec. 2025 was -120.44%. Vigonvita Life Sciences Co's PB Ratio for the quarter that ended in Dec. 2025 was 27.88.
Vigonvita Life Sciences Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -4.32%.
Vigonvita Life Sciences Co ROE % Adjusted to Book Value Related Terms
Vigonvita Life Sciences Co ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Vigonvita Life Sciences Co's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vigonvita Life Sciences Co ROE % Adjusted to Book Value Chart
Vigonvita Life Sciences Co Annual Data
Trend
Dec23
Dec24
Dec25
ROE % Adjusted to Book Value
0.00
0.00
-4.32
Vigonvita Life Sciences Co Semi-Annual Data
Dec23
Dec24
Dec25
ROE % Adjusted to Book Value
0.00
0.00
-4.32
HKSE:02630 vs LLY, JNJ, ABBV: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - General subindustry, Vigonvita Life Sciences Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vigonvita Life Sciences Co ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vigonvita Life Sciences Co's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Vigonvita Life Sciences Co's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -4.32% mean?
Vigonvita Life Sciences Co (HKSE:02630) has a ROE % Adjusted to Book Value of -4.32% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vigonvita Life Sciences Co and its competitors.
Is Vigonvita Life Sciences Co's ROE % Adjusted to Book Value too high?
Vigonvita Life Sciences Co's current ROE % Adjusted to Book Value is -4.32%. Overall, Vigonvita Life Sciences Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vigonvita Life Sciences Co's ROE % Adjusted to Book Value compare to LLY and JNJ?
Vigonvita Life Sciences Co's ROE % Adjusted to Book Value of -4.32% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vigonvita Life Sciences Co and its competitors. Vigonvita Life Sciences Co's current ROE % Adjusted to Book Value is -4.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vigonvita Life Sciences Co stock overvalued right now?
Vigonvita Life Sciences Co (HKSE:02630) has a current ROE % Adjusted to Book Value of -4.32%. The current ROE % Adjusted to Book Value is -4.32%. Vigonvita Life Sciences Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Vigonvita Life Sciences Co (HKSE:02630), the current ROE % Adjusted to Book Value is -4.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is focused on innovation driven biopharmaceutical development, with a strategic emphasis on addressing unmet clinical needs in the treatment of neuropsychiatric, infectious, and andrological diseases. The company's core Products include LV232, anti-depression drug candidate, VV913: a novel investigational drug candidate for premature ejaculation and, VV116: an oral nucleoside analog with broad-spectrum antiviral potential. The company's operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
8GF Score
Get the complete analysis for HKSE:02630
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02630 has been successfully added to your 
